# CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

> **NCT06420089** · PHASE1 · RECRUITING · sponsor: **Vittoria Biotherapeutics** · enrollment: 30 (estimated)

## Conditions studied

- T Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Senza5 CART5

## Key facts

- **NCT ID:** NCT06420089
- **Lead sponsor:** Vittoria Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-04
- **Primary completion:** 2028-08-30
- **Final completion:** 2029-08-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06420089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06420089, "CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06420089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*